Results 121 to 130 of about 880,423 (146)

[Study of No Observed Adverse Effect Level of Nickel and Its Preliminary Evaluation Biocompatibility].

Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation, 2020
The purpose of this study was to investigate the NOAEL of the nickel ion and provide with basic data for the biological evaluation of those medical devices containing nickel. Five groups SD rats were repeatedly exposed during 14 d respectively to nickel at first stage doses of 4.9, 3.7, 2.5 mg/(kg.d), and the second stage doses of 1.2, 0.25 mg/(kg.d ...
Xueying, He, Juli, Tang, Xiantao, Wen, Bo, Guan, Rui, Wang, Hui, Wang, Hua, Li, Jianfeng, Shi, Yali, Zeng, Yongjian, Mao   +9 more
openaire   +1 more source

Dose-Response Assessment for Developmental Toxicity II. Comparison of Generic Benchmark Dose Estimates with No Observed Adverse Effect Levels

Fundamental and Applied Toxicology, 1994
Developmental toxicity risk assessment currently relies on the estimation of reference doses (RfDDTS) of reference concentrations (RfCDTS) based on the use of no observed adverse effect levels (NOAELS) divided by uncertainty factors (UFs). The benchmark dose (BMD) has been proposed as an alternative basis for reference value calculations.
B C, Allen, R J, Kavlock, C A, Kimmel, E M, Faustman   +3 more
openaire   +2 more sources

The No-Observed-Adverse-Effect Level (NOAEL) of Baby Aloe Powder (BAP) for Nutraceutical Application Based Upon Toxicological Evaluation

Journal of Toxicology and Environmental Health, Part A, 2014
Aloe has been used in versatile herbal medications and nutraceuticals throughout history. Aloe is widely considered to be generally safe for humans and used globally. The effectiveness and pharmacological properties of aloe are dependent upon when the plant is collected.
Seung Jun, Kwack, Seon-Gil, Do, Young Woo, Kim, Yeon-Joo, Kim, Hyo-Min, Gwak, Hyun Jong, Park, Taehyun, Roh, Min Kyung, Shin, Seong Kwang, Lim, Hyung Sik, Kim, Byung-Mu, Lee   +10 more
openaire   +2 more sources

Comparing probabilistic and descriptive analyses of time–dose–toxicity relationship for determining no-observed-adverse-effect level in drug development

Toxicology and Applied Pharmacology, 2015
The no-observed-adverse-effect level (NOAEL) of a drug defined from animal studies is important for inferring a maximal safe dose in human. However, several issues are associated with its concept, determination and application. It is confined to the actual doses used in the study; becomes lower with increasing sample size or dose levels; and reflects ...
Glatard, A., Berges, A., Sahota, T., Ambery, C., Osborne, J., Smith, R., Henin, Emilie, Chen, C.   +7 more
openaire   +3 more sources

Statistical uncertainty in the no-observed-adverse-effect level*1

Fundamental and Applied Toxicology, 1989
openaire   +1 more source

Determining the No-Observed-Adverse-Effect Level in Continuous Response

1993
Yasuki Kikuchi, Takashi Yanagawa, Harutoshi Nishiyama   +2 more
openaire   +1 more source

No Observable Adverse Effect Level (NoAEL)

2011
openaire   +1 more source

No Observable Adverse Effect Level (NoAEL)

2006
openaire   +1 more source

No Observable Adverse Effect Level (NoAEL)

2015
openaire   +1 more source

Pharmacogenetics and pharmacogenomics of anticancer agents

Ca-A Cancer Journal for Clinicians, 2009
R Stephanie Huang
exaly